Identification of a novel variant of the RET proto-oncogene in a novel family with Hirschsprung’s disease
Sign Up to like & getrecommendations! Published in 2017 at "Pediatric Surgery International"
DOI: 10.1007/s00383-017-4134-z
Abstract: AbstractPurposeHirschsprung’s disease (HSCR) is a congenital disorder of the enteric nervous system characterized by the absence of ganglion cells in the Auerbach’s and Meissner’s plexuses. Although about 7% of cases are hereditary, the causal mutations… read more here.
Keywords: novel family; novel variant; disease; family ... See more keywords
KIF5B-RET Oncoprotein Signals through a Multi-kinase Signaling Hub.
Sign Up to like & getrecommendations! Published in 2017 at "Cell reports"
DOI: 10.1016/j.celrep.2017.08.037
Abstract: Gene fusions are increasingly recognized as important cancer drivers. The KIF5B-RET gene has been identified as a primary driver in a subset of lung adenocarcinomas. Targeting human KIF5B-RET to epithelia in Drosophila directed multiple aspects… read more here.
Keywords: kif5b ret; ret oncoprotein; signaling hub; oncoprotein signals ... See more keywords
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
Sign Up to like & getrecommendations! Published in 2018 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2018.02.080
Abstract: It is now known that "gain of function" mutations of RET (REarranged during Transfection) kinase are specific and key oncogenic events in the onset of thyroid gland cancers such as the Medullary Thyroid Carcinoma (MTC).… read more here.
Keywords: medullary thyroid; challenging clinically; clinically unresponsive; ret inhibitors ... See more keywords
Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
Sign Up to like & getrecommendations! Published in 2021 at "ESMO Open"
DOI: 10.1016/j.esmoop.2020.100041
Abstract: On 10 December 2020 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended granting a conditional marketing authorisation for selpercatinib (Retevmo) for the treatment of cancers that display… read more here.
Keywords: rethinking treatment; ret; treatment ret; thyroid ... See more keywords
Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medicinal Chemistry"
DOI: 10.1021/acs.jmedchem.9b01336
Abstract: RET receptor tyrosine kinase is a driver oncogene in human cancer. We recently identified the clinical drug candidate Pz-1, which targets RET and VEGFR2. A key in vivo metabolite of Pz-1 is its less active… read more here.
Keywords: discovery npa101; ret vegfr2; npa101 second; bioisosteric discovery ... See more keywords
Reticulocyte Hemoglobin Equivalent (Ret-He) Combined with Red Blood Cell Distribution Width Has a Differentially Diagnostic Value for Thalassemias
Sign Up to like & getrecommendations! Published in 2019 at "Hemoglobin"
DOI: 10.1080/03630269.2019.1655440
Abstract: Abstract As a type of congenital microcytic hypochromic anemia, thalassemia trait is often confused with other conditions, such as congenital sideroblastic anemia (CSA) and iron deficiency anemia, before a specific work-up is performed. However, these… read more here.
Keywords: anemia; thalassemia; value; thalassemia trait ... See more keywords
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016–present)
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Therapeutic Patents"
DOI: 10.1080/13543776.2022.2132851
Abstract: ABSTRACT Introduction Rearranged during transfection (RET) is a transmembrane receptor tyrosine kinase. Aberrations in RET signaling due to mutations, gene fusions, or overexpression can lead to carcinomas. Six inhibitors have been approved for the treatment… read more here.
Keywords: kinase; ret inhibitors; ret; rearranged transfection ... See more keywords
Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000031480
Abstract: Introduction: RET-rearranged fusions have been considered as oncogenic drivers in 1% to 2% of non-small cell lung cancers (NSCLC). ARROW study has demonstrated a new selective RET tyrosine kinase inhibitors (TKIs) shows remarkable and durable… read more here.
Keywords: ccdc6; ret; patient; case ... See more keywords
MAB21L4 deficiency drives squamous cell carcinoma via activation of RET.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer research"
DOI: 10.1158/0008-5472.can-22-0047
Abstract: Epithelial squamous cell carcinomas (SCC) most commonly originate in the skin, where they display disruptions in the normally tightly regulated homeostatic balance between keratinocyte proliferation and terminal differentiation. We performed a transcriptome-wide screen for genes… read more here.
Keywords: scc; squamous cell; ret; differentiation ... See more keywords
Progresses Toward Precision Medicine in RET-altered Solid Tumors
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-1587
Abstract: RET (rearranged during transfection) gene encodes a receptor tyrosine kinase essential for many physiologic functions, but RET aberrations are involved in many pathologies. While RET loss-of-function mutations are associated with congenital disorders like Hirschsprung disease… read more here.
Keywords: toward precision; medicine; precision medicine; ret ... See more keywords
ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2
Sign Up to like & getrecommendations! Published in 2021 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-20-0386
Abstract: Gain-of-function point mutations in the receptor tyrosine kinase RET, a driver oncogene in medullary thyroid carcinoma (MTC), prevent apoptosis through inhibition of ATF4, a critical transcriptional regulator of endoplasmic reticulum stress. However, the critical regulatory… read more here.
Keywords: mtc; vegfr2 igfbp2; vegfr2; ret ... See more keywords